Saliminejad Kioomars, Mahmoodzadeh Habibollah, Soleymani Fard Shahrzad, Yaghmaie Marjan, Khorram Khorshid Hamid Reza, Mousavi Seyed Asadollah, Vaezi Mohammad, Ghaffari Seyed Hamidollah
Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Avicenna J Med Biotechnol. 2022 Oct-Dec;14(4):278-286.
The high mortality rate of Gastric Cancer (GC) is a consequence of delayed diagnosis. The early diagnosis of GC could increase the five-year survival rate among patients. We aimed to find a panel of microRNAs (miRNA) for the detection of GC in the early stages.
In this case-control study, we selected consistently upregulated miRNAs from the results of 12 high-throughput miRNA profiling studies in GC. In the profiling phase, the differential expressions of 13 candidate miRNAs were analyzed by quantitative reverse-transcription PCR (qRT-PCR) in two pooled RNA samples prepared from the plasma of eight GC patients and eight matched controls. In the validation phase, significantly upregulated miRNAs from the profiling phase were further evaluated in the plasma samples of 97 patients with stage I-IV gastric adenocarcinoma and 100 healthy controls.
In the profiling phase, six miRNAs (miR-18a, 21, 25, 92a, 125b and 221) were significantly upregulated in the GC patients compared to the controls (p<0.05). However, in the validation phase, only significant up-regulation of miR-18a, 21 and 125b was confirmed (p<0.05). A panel of miR-18a/21/125b was able to detect GC patients with stage I-IV from the controls (p<0.001; AUC=0.92, sensitivity=86%; specificity=85%). In addition, the panel could distinguish the early-stage GC (I+II) from the control group with an AUC of 0.83, a sensitivity of 83%, and a specificity of 75%.
A panel of circulating miR18a/21/125b could be suggested as a potential biomarker for the early detection of GC.
胃癌（GC）的高死亡率是诊断延迟的结果。GC的早期诊断可提高患者的五年生存率。我们旨在寻找一组用于早期检测GC的微小RNA（miRNA）。
在这项病例对照研究中，我们从12项GC高通量miRNA谱研究结果中筛选出持续上调的miRNA。在谱分析阶段，通过定量逆转录PCR（qRT-PCR）分析了从8例GC患者和8例匹配对照的血浆中制备的两个混合RNA样本中13种候选miRNA的差异表达。在验证阶段，对97例I-IV期胃腺癌患者和100例健康对照的血浆样本进一步评估谱分析阶段显著上调的miRNA。
在谱分析阶段，与对照组相比，GC患者中有6种miRNA（miR-18a、21、25、92a、125b和221）显著上调（p<0.05）。然而，在验证阶段，仅证实miR-18a、21和125b有显著上调（p<0.05）。一组miR-18a/21/125b能够从对照组中检测出I-IV期的GC患者（p<0.001；AUC=0.92，敏感性=86%；特异性=85%）。此外，该组miRNA能够将早期GC（I+II期）与对照组区分开来，AUC为0.83，敏感性为83%，特异性为75%。
循环miR18a/21/125b组可作为GC早期检测的潜在生物标志物。
